J Dingemanse

Summary

Affiliation: University of Basel
Country: Switzerland

Publications

  1. pmc Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects
    Jasper Dingemanse
    Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland
    Br J Clin Pharmacol 61:405-13. 2006
  2. ncbi request reprint Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects
    J Dingemanse
    Jacor Research, Bottmingen, Switzerland
    Drug Metab Dispos 28:1411-6. 2000
  3. pmc Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin
    Jasper Dingemanse
    Jacor Research, Bottmingen, Switzerland
    Br J Clin Pharmacol 53:485-91. 2002
  4. ncbi request reprint Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease
    J Dingemanse
    Clin Pharma Research Ltd, Birsfelden, Switzerland
    Eur Neurol 39:119-24. 1998
  5. ncbi request reprint Multiple-dose tolerability, pharmacodynamics, and pharmacokinetics of the quinolizinone hypnotic Ro 41-3696 in elderly subjects
    J Dingemanse
    Jacor Research, Bottmingen, Switzerland
    Clin Neuropharmacol 24:82-90. 2001
  6. ncbi request reprint Clinical pharmacology of bosentan, a dual endothelin receptor antagonist
    Jasper Dingemanse
    Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    Clin Pharmacokinet 43:1089-115. 2004
  7. ncbi request reprint Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects
    Paul L M van Giersbergen
    Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Gewerbestrasse 18, 4123 Allschwil, Switzerland
    J Clin Pharmacol 45:42-7. 2005
  8. ncbi request reprint Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist
    Paul L M van Giersbergen
    Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 18, 4123 Allschwil, Switzerland
    Eur J Clin Pharmacol 63:151-8. 2007
  9. ncbi request reprint Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase
    Paul L M van Giersbergen
    Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Gewerbestrasse 16, 4123 Allschwil, Switzerland
    J Clin Pharmacol 47:1277-82. 2007
  10. ncbi request reprint Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil
    Gary Burgess
    PGRD, Pfizer Ltd, Sandwich, Kent, UK
    Eur J Clin Pharmacol 64:43-50. 2008

Collaborators

Detail Information

Publications19

  1. pmc Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects
    Jasper Dingemanse
    Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland
    Br J Clin Pharmacol 61:405-13. 2006
    ..To investigate the pharmacokinetics, pharmacodynamics and tolerability of the dual endothelin receptor antagonist tezosentan in caucasian and Japanese subjects...
  2. ncbi request reprint Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects
    J Dingemanse
    Jacor Research, Bottmingen, Switzerland
    Drug Metab Dispos 28:1411-6. 2000
    ..The relatively slow absorption of Ro 41-3290 (t(max) approximately 2.5 h) and the concentration-effect time delay do not make it a good candidate to replace its parent compound Ro 41-3696 as an investigational hypnotic...
  3. pmc Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin
    Jasper Dingemanse
    Jacor Research, Bottmingen, Switzerland
    Br J Clin Pharmacol 53:485-91. 2002
    ..To investigate the influence of a multiple-dose regimen with the catechol-O-methyltransferase inhibitor entacapone on the pharmacokinetics and pharmacodynamics of warfarin...
  4. ncbi request reprint Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease
    J Dingemanse
    Clin Pharma Research Ltd, Birsfelden, Switzerland
    Eur Neurol 39:119-24. 1998
    ..In conclusion, the release characteristics in healthy subjects of the new levodopa/benserazide formulation are influenced only to a minor extent by concomitant intake of food or by tablet breaking...
  5. ncbi request reprint Multiple-dose tolerability, pharmacodynamics, and pharmacokinetics of the quinolizinone hypnotic Ro 41-3696 in elderly subjects
    J Dingemanse
    Jacor Research, Bottmingen, Switzerland
    Clin Neuropharmacol 24:82-90. 2001
    ....
  6. ncbi request reprint Clinical pharmacology of bosentan, a dual endothelin receptor antagonist
    Jasper Dingemanse
    Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    Clin Pharmacokinet 43:1089-115. 2004
    ..In a pharmacokinetic-pharmacodynamic study in PAH patients, the haemodynamic effects lagged the plasma concentrations of bosentan...
  7. ncbi request reprint Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects
    Paul L M van Giersbergen
    Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Gewerbestrasse 18, 4123 Allschwil, Switzerland
    J Clin Pharmacol 45:42-7. 2005
    ..The results suggest that, based on pharmacokinetic grounds, no dose adjustment of bosentan is necessary when used to treat Japanese patients in comparison to Caucasian patients...
  8. ncbi request reprint Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist
    Paul L M van Giersbergen
    Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 18, 4123 Allschwil, Switzerland
    Eur J Clin Pharmacol 63:151-8. 2007
    ..The purpose of this study was to investigate in healthy male subjects the tolerability, pharmacokinetics, and pharmacodynamics of ascending doses of clazosentan, an intravenous endothelin receptor antagonist...
  9. ncbi request reprint Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase
    Paul L M van Giersbergen
    Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Gewerbestrasse 16, 4123 Allschwil, Switzerland
    J Clin Pharmacol 47:1277-82. 2007
    ..The observed effects of food intake on the pharmacokinetics of miglustat are not considered to be of clinical relevance...
  10. ncbi request reprint Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil
    Gary Burgess
    PGRD, Pfizer Ltd, Sandwich, Kent, UK
    Eur J Clin Pharmacol 64:43-50. 2008
    ....
  11. ncbi request reprint The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure
    Gad Cotter
    The Cardiology Department, Assaf Harofeh Medical Center, 70300 Zerifin, Israel
    Eur J Heart Fail 6:601-9. 2004
    ..v.)-balanced dual endothelin (ET-A/B) antagonist, in doses of 50 and 100 mg/h, improved the hemodynamics but not the clinical outcome of patients with acute heart failure (AHF)...
  12. ncbi request reprint Multiple-dose pharmacokinetics of intranasally administered IS-159 in healthy subjects
    Paul L M van Giersbergen
    The Medicines Company, Gasstrasse 1, CH 4056 Basel, Switzerland
    Eur J Drug Metab Pharmacokinet 28:49-54. 2003
    ..The results showed dose-proportional pharmacokinetics of IS-159 in the dose range tested and a low propensity for drug accumulation...
  13. ncbi request reprint Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin
    Jasper Dingemanse
    Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    Clin Pharmacokinet 42:293-301. 2003
    ..In vitro, bosentan has been shown to be a mild inducer of cytochrome P450 (CYP) 2C9 and 3A4...
  14. pmc Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole
    Paul L M van Giersbergen
    Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Gewerbestrasse 18, 4123 Allschwil, Switzerland
    Br J Clin Pharmacol 53:589-95. 2002
    ..The present study was conducted to characterize the single- and multiple-dose pharmacokinetics of bosentan, a dual endothelin receptor antagonist, and to investigate a possible pharmacokinetic interaction with ketoconazole...
  15. ncbi request reprint Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist
    Jasper Dingemanse
    Actelion Pharmaceuticals Ltd, Department of Preclinical Pharmacology, Allschwil, Switzerland
    J Cardiovasc Pharmacol 39:795-802. 2002
    ..Tezosentan warrants further clinical development in view of its tolerability and pharmacokinetic profile, which appears advantageous for application in emergency situations...
  16. pmc Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects
    Jasper Dingemanse
    Actelion Pharmaceuticals Ltd, Department of Preclinical Pharmacology, Gewerbestrasse 18, 4123 Allschwil, Switzerland
    Br J Clin Pharmacol 53:355-62. 2002
    ..The purpose of this study was to investigate the tolerability, pharmacokinetics, and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, during chronic infusions in healthy male subjects...
  17. ncbi request reprint In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide
    Paul L M van Giersbergen
    Department of Preclinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    Clin Pharmacol Ther 71:253-62. 2002
    ..This study was conducted to investigate a possible pharmacokinetic interaction between bosentan and glyburide...
  18. ncbi request reprint Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist
    Jasper Dingemanse
    Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland
    J Clin Pharmacol 42:283-9. 2002
    ..In conclusion, bosentan bioavailability from the newly developed 125 mg tablet formulation is similar to that of the suspension, and food intake does not influence its pharmacokinetics to a clinically relevant extent...
  19. doi request reprint Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects
    Rebecca E Wrishko
    Lilly Research Laboratories, Lilly Corporate Center, DC 0730, Indianapolis, IN 46285, USA
    J Clin Pharmacol 48:610-8. 2008
    ..In conclusion, after 10 days of coadministration, bosentan decreased tadalafil exposure by 41.5% with minimal and clinically irrelevant differences (<20%) in bosentan exposure...